公司資料
Candel Therapeutics 股價、新聞與催化劑
- 股票代碼:
- CADL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
12.16 USD (+3.75%)
收盤價
最後更新: 2026年8月17日
617M USD
市值
股價為何變動
As of Aug 17, 2026, CADL closed up 3.75% at $12.16. No new same-company headline was identified in the current news window.
公司概覽
Multimodal Cancer Immunotherapy
Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response.
Aglatimagene Besadenovec
Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into tumors. It is paired with valacyclovir to trigger local cytotoxicity and immune activation.
Prostate Cancer Program
A pivotal Phase 3 study demonstrated improved disease-free survival when aglatimagene was added to radiotherapy in localized intermediate- to high-risk prostate cancer. The company is preparing a BLA based on this program.
Lung Cancer Expansion
The global Phase 3 AURORA study evaluates aglatimagene in advanced non-squamous non-small-cell lung cancer progressing after pembrolizumab.
Linoserpaturev
Linoserpaturev is a replication-competent oncolytic herpes-simplex-virus therapy in development for recurrent glioblastoma and other solid tumors.
未來催化劑
- Submission of a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026.
- Potential U.S. commercial launch of aglatimagene in 2027, subject to approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。